Thrasos Therapeutics, a US-based biotherapeutics company developing treatments for kidney disease, has closed a $21m series D round co-led by SR One, the corporate venturing arm of pharmaceutical company GlaxoSmithKline.
BDC Capital, a subsidiary of the Business Development Bank of Canada, co-led the round which will support a Phase 2 clinical trial of a treatment for the prevention of acute kidney injury.
In 2012, Thrasos secured a $35m series C round led by SR One and featuring SW Company, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, Pappas Venture and MP Healthcare Venture Management, the jointly-owned corporate venturing subsidiary of Mitsubishi Tanabe Pharma and parent company Mitsubishi Chemical Holdings.
According to a regulatory filing, Thrasos obtained a $10m series B round in 2010.
Thrasos’ lead drug candidate, THR-184, is currently undergoing a Phase 2 clinical trial in the US and Canada. The drug is aimed at the prevention of acute kidney injury in patients undergoing cardiac surgery. The renal failure, which can also be caused by a range of other issues including low blood pressure, is an abrupt loss of kidney function that occurs within seven days.